4.11.2Segment

Animal Health Pharmaceuticals

Animal pharmaceutical companies developing and commercializing vaccines, biologics, and medications for companion and livestock animals.

4
Verticals

Overview

Animal Health Pharmaceuticals covers companies developing and commercializing vaccines, biologics, parasiticides, and medications for companion and livestock animals. Across companion and production animals, it is led by global strategics: Zoetis (the leader, spun out of Pfizer), Boehringer Ingelheim, Elanco, and Merck Animal Health.

Companion-animal pharma is the growth engine, propelled by pet humanization and novel therapies (monoclonal antibodies for osteoarthritis pain like Librela/Solensia, dermatology, and parasiticides), while production-animal pharma is more mature and pressured by antibiotic-reduction trends. It is R&D-intensive, regulated, and consolidated.

Market snapshot

FragmentationConsolidatedEstimate

Within pharmaceutical manufacturing (NAICS 325412/325414); the Census Bureau does not separate animal-health pharmaceuticals, so the segment is not separately sized here.

Business model & economics

Revenue model

Vaccine, parasiticide, and therapeutic product sales

Key economics

Recurring revenue
High

recurring vaccines, parasiticides, and chronic meds

EBITDA margin
Strong

branded animal-pharma economics

Capex intensity
High

Characteristics

  • Companion-animal pharma the growth engine.
  • Novel therapies (mAbs, derm, parasiticides) drive growth.
  • Production-animal pharma mature and antibiotic-pressured.

Geographic concentration

AlabamaAlaskaArizonaFloridaGeorgiaIndianaKansasMaineMinnesotaNorth CarolinaNorth DakotaOklahomaPennsylvaniaSouth DakotaTexasWyomingConnecticutMissouriWest VirginiaIllinoisNew MexicoArkansasCaliforniaDelawareDistrict of ColumbiaHawaiiIowaKentuckyMarylandMichiganMississippiMontanaNew HampshireNew YorkOhioOregonTennesseeVirginiaWashingtonWisconsinNebraskaSouth CarolinaIdahoNevadaVermontLouisianaRhode IslandColoradoMassachusettsNew JerseyUtah

Animal-health pharmaceutical makers cluster in New Jersey and Massachusetts (human-pharma spillover), with specialized hubs in Utah and Colorado.

New JerseyMassachusettsUtahColorado

U.S. Census Bureau, 2022 Statistics of U.S. Businesses (firms by state), NAICS 325412/325414. Concentration shown by location quotient.

M&A deal context

Deal activityHigh

Who’s acquiring

  • Animal-health pharma strategics
  • Pharma & diversified acquirers
  • PE- and VC-backed innovators

What’s driving deals

  • Companion-animal novel-therapy innovation.
  • Consolidation around global strategics.
  • Acquisition of pet-pharma and biologic innovation.

Verticals in this segment

Find Animal Health Pharmaceuticals acquisition targets

Search Acquisera’s index for companies classified under Animal Health Pharmaceuticals (4.11.2) and build a targeted deal pipeline.

Search companies